Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia

被引:53
作者
Chen, Mo [1 ]
Ye, Chenyi [2 ]
Zhu, Jianing [1 ]
Zhang, Peiyu [1 ]
Jiang, Yujie [1 ]
Lu, Xiaoyong [1 ]
Wu, Huaxiang [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Rheumatol, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthoped, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
hyperuricemia; bergenin; ABCG2; urate-lowering therapeutic; URIC-ACID; PPAR-GAMMA; IN-VITRO; SLC2A9; SIRT1; MECHANISMS; CELLS; GOUT;
D O I
10.3389/fcell.2020.00703
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Bergenin is a C-glucoside of 4-O-methyl gallic acid isolated from several medicinal plants and has multiple biological activities. The aim of this study was to assess the potential usefulness of bergenin in hyperuricemia. We found that bergenin reduced serum urate levels in hyperuricemia mice by promoting renal and gut uric acid excretion. Bergenin treatment increasedAbcg2expression both in the kidneys and intestine, while the expression ofSlc2a9was suppressed in the kidney and increased in the intestine. Moreover, bergenin inducedABCG2expression in HK-2 and Caco-2 cells, as well asSLC2A9in Caco-2 cells, via the activation ofPPAR gamma. Nevertheless, bergenin suppressedSLC2A9expression in HK-2 cells by inhibiting the nuclear translocation of p53. Furthermore, bergenin decreased the serum levels of IL-6, IL-1 beta, and TNF-alpha in hyperuricemia mice, and promoted a polarization shift from the M1 to M2 phenotype in RAW264.7 cells. In conclusion, these findings provide evidence supporting the further development of bergenin as a novel therapeutic strategy for hyperuricemia.
引用
收藏
页数:13
相关论文
共 45 条
[1]
[Anonymous], 2017, P NATL ACAD SCI USA, DOI [DOI 10.1073/pnas.1620910114, DOI 10.1073/PNAS.1712064115]
[2]
Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies [J].
Barai, Priyal ;
Raval, Nisith ;
Acharya, Sanjeev ;
Borisa, Ankit ;
Bhatt, Hardik ;
Acharya, Niyati .
BEHAVIOURAL BRAIN RESEARCH, 2019, 356 :18-40
[3]
The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
[4]
Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway [J].
Chen, Mo ;
Lu, Xiaoyong ;
Lu, Ci ;
Shen, Ning ;
Jiang, Yujie ;
Chen, Menglu ;
Wu, Huaxiang .
ARTHRITIS RESEARCH & THERAPY, 2018, 20
[5]
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016 [J].
Chen-Xu, Michael ;
Yokose, Chio ;
Rai, Sharan K. ;
Pillinger, Michael H. ;
Choi, Hyon K. .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (06) :991-999
[6]
L-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate [J].
Chou, Hsiu-Chu ;
Wen, Li-Li ;
Chang, Chih-Cheng ;
Lin, Chien-Yu ;
Jin, Lu ;
Juan, Shu-Hui .
TOXICOLOGICAL SCIENCES, 2017, 160 (02) :217-229
[7]
Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra [J].
Crisan, Tania O. ;
Cleophas, Maartje C. P. ;
Oosting, Marije ;
Lemmers, Heidi ;
Toenhake-Dijkstra, Helga ;
Netea, Mihai G. ;
Jansen, Tim L. ;
Joosten, Leo A. B. .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (04) :755-762
[8]
Dalbeth N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0115-y, 10.1038/s41572-019-0124-x]
[9]
Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9 [J].
DeBosch, Brian J. ;
Kluth, Oliver ;
Fujiwara, Hideji ;
Schuermann, Annette ;
Moley, Kelle .
NATURE COMMUNICATIONS, 2014, 5
[10]
Homozygous SLC2A9 Mutations Cause Severe Renal Hypouricemia [J].
Dinour, Dganit ;
Gray, Nicola K. ;
Campbell, Susan ;
Shu, Xinhua ;
Sawyer, Lindsay ;
Richardson, William ;
Rechavi, Gideon ;
Amariglio, Ninette ;
Ganon, Liat ;
Sela, Ben-Ami ;
Bahat, Hilla ;
Goldman, Michael ;
Weissgarten, Joshua ;
Millar, Michael R. ;
Wright, Alan F. ;
Holtzman, Eliezer J. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (01) :64-72